317 related articles for article (PubMed ID: 9887242)
1. The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?
Ivarsson K; Runesson E; Sundfeldt K; Haeger M; Hedin L; Janson PO; Brännström M
Gynecol Oncol; 1998 Dec; 71(3):420-3. PubMed ID: 9887242
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
3. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
Hazelton D; Nicosia RF; Nicosia SV
Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2006 Sep; 102(3):542-5. PubMed ID: 16510173
[TBL] [Abstract][Full Text] [Related]
7. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
Menczer J; Ben-Baruch G; Moran O; Lipitz S
Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
[TBL] [Abstract][Full Text] [Related]
8. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2005 Feb; 96(2):516-9. PubMed ID: 15661245
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Eur J Obstet Gynecol Reprod Biol; 2008 Sep; 140(1):67-70. PubMed ID: 16359773
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.
Lambeck AJ; Crijns AP; Leffers N; Sluiter WJ; ten Hoor KA; Braid M; van der Zee AG; Daemen T; Nijman HW; Kast WM
Clin Cancer Res; 2007 Apr; 13(8):2385-91. PubMed ID: 17438097
[TBL] [Abstract][Full Text] [Related]
11. Serum C-reactive protein in the differential diagnosis of ovarian masses.
Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
[TBL] [Abstract][Full Text] [Related]
12. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.
Sundfeldt K; Ivarsson K; Rask K; Haeger M; Hedin L; Brännström M
Anticancer Res; 2001; 21(1A):65-70. PubMed ID: 11299791
[TBL] [Abstract][Full Text] [Related]
13. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
14. Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.
Arts HJ; de Jong S; Hollema H; Ten Hoor KA; de Vries EG; van der Zee AG
Int J Oncol; 2005 Feb; 26(2):379-84. PubMed ID: 15645122
[TBL] [Abstract][Full Text] [Related]
15. [Sialic acid concentrations in blood samples as well as in cyst and peritoneal fluid in patients with ovarian cysts and cystic ovarian tumors].
Strache RR; Büttner HH; Göcze PM; Briese V
Zentralbl Gynakol; 1990; 112(23):1445-53. PubMed ID: 2291368
[TBL] [Abstract][Full Text] [Related]
16. [Placental protein 12 (PP 12) in cyst and peritoneal fluids and serum samples of patients with ovarian cysts and cystic ovarian tumors].
Strache RR; Göcze PM; Szábo DG; Büttner HH; Briese V; Kunze M; Csaba IF; Röpcke G
Zentralbl Gynakol; 1989; 111(11):749-54. PubMed ID: 2781888
[TBL] [Abstract][Full Text] [Related]
17. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
Kolwijck E; Zusterzeel PL; Roelofs HM; Hendriks JC; Peters WH; Massuger LF
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2176-81. PubMed ID: 19661073
[TBL] [Abstract][Full Text] [Related]
18. [CEA determination in aspired fluid of cystic ovarian tumors and ovarian cysts and in ascites and serum samples of patients with ovarian tumors].
Kunze M; Büttner HH; Strache RR; Voss P; Briese V; Schrodt U
Zentralbl Gynakol; 1988; 110(16):1006-12. PubMed ID: 3188713
[TBL] [Abstract][Full Text] [Related]
19. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
20. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]